Since the beginning of January 2020, Rallis has moved up by 32% at a time when the market overall is down by over 20%. The triggers appear to be largely fundamental, although the lockdown could have temporarily created challenges for the stock. For the March quarter, Rallis is expected to post 12% YOY growth in revenues amid continued growth from a robust Rabi season. Of course, this could be partly offset by disruption in logistics and shutdown of operations in March-end 2020. While the top line is expected to grow moderately, the real growth of over 200% could be seen in EBITDA, which is what the markets have been betting on. The markets are also betting positively on expansion of Metribuzin capacity by Rallis, which will be a big boost to the international business of Rallis.
Since the beginning of January 2020, Rallis has moved up by 32% at a time when the market overall is down by over 20%. The triggers appear to be largely fundamental, although the lockdown could have temporarily created challenges for the stock. For the March quarter, Rallis is expected to post 12% YOY growth in revenues amid continued growth from a robust Rabi season. Of course, this could be partly offset by disruption in logistics and shutdown of operations in March-end 2020. While the top line is expected to grow moderately, the real growth of over 200% could be seen in EBITDA, which is what the markets have been betting on. The markets are also betting positively on expansion of Metribuzin capacity by Rallis, which will be a big boost to the international business of Rallis.